Immediate Risk of Cervical Precancer and Primary Triage Strategies for Women with Non- 16/18 High-Risk HPV Infection and ASC-US/LSIL Cytology: A Real-World Cross-Sectional Study
Objective We evaluated the immediate risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) conferred by non-16/18 high-risk HPV (hrHPV) genotypes in women with atypical squamous cells of undetermined significance (ASC-US) and low-grade squamous intraepithelial lesion (LSIL) cytology, and developed a risk-based primary triage strategy. We also characterized the regional epidemiological features of HPV infection in Ningbo, China, from 2019 to 2024. Methods Based on defined eligibility criteria, this study enrolled 511,133 women participating in cervical cancer screening in Ningbo from 2019 to 2024. Colposcopy and histopathological biopsy were performed based on HPV and liquid-based cytology (TCT) findings. We used lowest-attribution (minimum), any-attribution, and hierarchical-attribution models to evaluate the distribution of non-16/18 hrHPV genotypes and their immediate risks of progressing to CIN2 + under ASC-US and LSIL cytology. Finally, we formulated a risk-stratified clinical triage framework by integrating recent evidence on extended HPV genotyping. Results Of 511,133 women screened, 50,320 (9.84%) were HPV-positive, with HPV52, 58, and 16 identified as the predominant genotypes. Non-16/18 hrHPV accounted for 84.18% (42,357/50,320) of all HPV-positive cases. Across both ASC-US and LSIL cytology, HPV31 conferred the highest immediate risk of CIN2 + among all non-16/18 genotypes. Conclusion Although non-16/18 hrHPV genotypes predominate among HPV-positive women, their immediate risks of CIN2 + are highly heterogeneous. A uniform management protocol for managing non-16/18 hrHPV infections wastes medical resources. We propose a three-tiered, extended genotyping-based triage strategy for women with ASC-US/LSIL cytology: direct colposcopy for high-risk genotypes (HPV31, 33, 52, and 58); conservative follow-up for low-risk genotypes (HPV39, 56, 66, and 68); and secondary triage using biomarkers (e.g., DNA methylation, p16/Ki-67 dual staining) or cytology for intermediate-risk genotypes. This framework is designed for initial, immediate triage and does not replace long-term longitudinal surveillance for specific genotypes.
Authors
- Jue Zhu (ORCID: https://orcid.org/0000-0003-3410-4257)
- Yichen Chen
- Linghui Weng
- Liang Chen
- Liping Chen
- Jing Zhang
- Jun Ma
- Xiao Li
Institutions
- Ningbo University (CN)
- Women's Hospital, School of Medicine, Zhejiang University (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11677277/v1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- preprint